Lineage Cell The Stock Price, News & Analysis

Lineage Cell Therapeutics (LCTX) has been added to the Russell 3000® and Russell Microcap® Indexes, effective today. This inclusion is a recognition of Lineage's progress in the field of cell therapy and regenerative medicine, with CEO Brian M. Culley emphasizing growth opportunities that could enhance investor awareness and liquidity. The Russell indexes capture the largest U.S. stocks based on market capitalization, affecting $10.6 trillion in assets. Lineage's diverse clinical pipeline includes therapies for dry age-related macular degeneration, spinal cord injuries, and lung cancer.

Lineage Cell Therapeutics (NYSE American: LCTX) announced progress on its OPC1 therapy for spinal cord injury (SCI). Following recent FDA feedback, the company plans to submit an IND amendment for a Phase 1 study utilizing Neurgain Technologies' delivery system. This study aims to evaluate the safety and efficacy of OPC1, with expectations to initiate a late-stage trial in 2022. Improvements in OPC1 cell production have been noted, and broader patient eligibility is anticipated. The Neurgain delivery system aims to enhance surgical precision without interrupting patients' breathing.

Lineage Cell Therapeutics (LCTX) has granted Amasa Therapeutics an exclusive option for a license to its HyStem technology aimed at treating solid tumors. This agreement includes an upfront cash payment, potential event-specific payments, and royalties on net sales if exercised. HyStem mimics the extracellular matrix, aiding in cell retention and viability for therapies targeting cancers like glioblastoma. This partnership enhances LCTX's position in oncology, while Amasa aims to expedite its clinical developments using HyStem's biomaterials.

Lineage Cell Therapeutics (NYSE American: LCTX) announced the appointment of Kevin Cook as the new Chief Financial Officer, effective June 21, 2021. With over 20 years of experience in strategic and operational roles, Cook has managed over $30 billion in capital raising, particularly in the life sciences sector. CEO Brian Culley expressed confidence in Cook's ability to support the company's growth as it advances its clinical programs, which include therapies for degenerative diseases. Lineage aims to become a leader in cell therapy, focusing on unmet medical needs.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. ET. Investors can access the presentation live and archived on the company's Events and Presentations webpage. Lineage develops allogeneic cell therapies targeting significant medical needs, with products like OpRegen, OPC1, and VAC2 currently in Phase 1/2a clinical trials.

Lineage Cell Therapeutics (LCTX) announced its inclusion in the Russell 3000 and Russell Microcap Indexes, effective June 28, 2021. This recognition highlights the company's advancements in developing allogeneic cell therapies. The Russell Indexes encompass the largest U.S. stocks, with membership potentially enhancing investor outreach and liquidity. CEO Brian M. Culley stated that this achievement reflects the company’s progress and aims to capitalize on the growing field of cell therapy. The Russell Indexes influence substantial assets, with about $10.6 trillion benchmarked against them.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a webinar on June 10, 2021, at 4 PM ET, featuring experts discussing age-related macular degeneration (AMD). The company reported successful retinal tissue restoration in three patients from its OpRegen Phase 1/2a study for dry AMD, with integration of new retinal pigment epithelium cells observed. This indicates potential efficacy for OpRegen, aimed at addressing unmet medical needs in AMD treatment. The webinar will present detailed results and anatomical improvements related to OpRegen therapy.

Lineage Cell Therapeutics (LCTX) reported positive outcomes in its Phase 1/2a study of OpRegen for treating dry age-related macular degeneration (AMD). Restoration of retinal tissue was observed in two Cohort 4 patients, with significant improvements in visual acuity noted within six months. This suggests that atrophic AMD may not be irreversibly degenerative. The company has also filed a PCT patent application to protect these findings. The therapy demonstrated safety with no unexpected adverse events over more than five years of follow-up.

Lineage Cell Therapeutics, a clinical-stage biotech company, reported Q1 2021 financial results with total revenues of approximately $0.4 million, down from $0.5 million in Q1 2020, mainly due to decreased grant income. Operating expenses decreased to $7.3 million, while R&D expenses increased slightly to $3.4 million. The net loss attributable to Lineage was $1.4 million, improved from a $8.4 million loss in Q1 2020. The company highlighted operational progress in its clinical programs, particularly OpRegen, associated partnerships, and a strong cash position of $62.4 million.